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E-mail address: yptsao@yahoo.com (Y.-P. Tsao).This study was designed to evaluate the efﬁcacy of subretinal injection of recombinant adeno-associated
virus vector expressing heme oxygenase-1 (rAAV-HO-1) in attenuating photoreceptor apoptosis induced
by experimental retinal detachment (RD) in Sprague–Dawley rats. Our results disclosed that subretinal
rAAV-HO-1 delivery achieved localized high HO-1 gene expression in retinal outer nuclear layer (ONL)
compared with rAAV-lacZ-injected eyes and eyes with RD left untreated both at 2 (p = 0.003) and 28
(p = 0.007) days of RD. The ONL thickness (p = 0.018) and mean photoreceptor nuclei count (p = 0.009)
in eyes receiving rAAV-HO-1 injection was signiﬁcantly higher than in rAAV-lacZ-injected or eyes with
RD left untreated at 28 days of RD. There were fewer apoptotic photoreceptor nuclei at 2 (p = 0.008)
and 5 (p = 0.018) days of RD and less activated caspase-3 expression (p = 0.008) at 2 days of RD in
rAAV-HO-1 treated eyes than in control eyes. These data supported that gene transfer approach might
attenuate photoreceptor apoptosis caused by RD with a resultant better ONL preservation.
 2008 Elsevier Ltd. All rights reserved.1. Introduction
Retinal detachment (RD), the separation of the neurosensory
retina from the retinal pigment epithelium (RPE), is a common
cause of human visual impairment Hassan et al., 2002; Lewis,
Charteris, Sethi, & Fisher, 2002; The Eye Disease Case-Control
Study Group., 1993. Due to the recent advancements, the surgical
outcome for RD is largely improved, and is associated with fewer
complications (Brazitikos, 2000). However, some patients experi-
ence visual impairment despite successful reattachment surgery.
The retinal cells that are most susceptible to detachment are
photoreceptors, Müller cells and RPE cells (Fisher, Lewis, Linberg,
& Verardo, 2005). Evidences show that photoreceptors continue to
undergo cell death after detachment (Cook, Lewis, Fisher, & Adler,
1995; Fisher & Anderson, 2001; Hisatomi et al., 2002), and there is
a steady decline in the thickness of the retinal outer nuclear layerll rights reserved.
hthalmology, Mackay Memo-
Taipei, Taiwan. Fax: +886 2(ONL) after RD (Erickson, Fisher, Anderson, Stern, & Borgula, 1983;
Kubay, Charteris, Newland, & Raymond, 2005; Tanelian, Barry,
Johnston, Le, & Smith, 1997. Photoreceptor cell death after RD has
been shown to be associated with apoptosis (Chang, Lai, Edward,
& Tsao, 1995; Cook et al., 1995) and is implicated with the poor vi-
sual prognosis after RD (Fisher et al., 2005). Several mediators such
as ﬁbroblast growth factor Li, Chang, & Milam, 1997, ciliary-associ-
ated neurotrophic factor Richardson, 1994, brain-derived neurotro-
phic factor (Lewis, Linberg, Geller, Guerin, & Fisher, 1999), and
insulin-like growth factor (Burren, Berka, Edmondson, Werther, &
Batch, 1996) have been used to reduce the damage to photorecep-
tors induced by RD in animal studies. Previously, we have reported
the use of recombinant adeno-associated virus (rAAV) as a vector
expressing glial cell-line-derived neurotrophic factor to protect
photoreceptors from apoptosis in experimental RD (Wu et al, 2002).
The heme oxygenase (HO) is a regulator of oxidative stress
(Morita, Perrella, Lee, & Kourembanas, 1995; Otterbein & Choi,
2000; Otterbein et al., 2000; Stocker, Yamamoto, McDonagh, Gla-
zer, & Ames, 1987). HO catalyzes the oxidative degradation of
heme to biliverdin, carbon monoxide (CO), and iron (Guo et al.,
2004; Togane et al., 2000). The heme oxygenase-1 (HO-1) is the
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1987) and heme oxygenase-2 (HO-2) is the basal constituent iso-
enzyme of HO (Maines, Trakshel, & Kutty, 1986). Inhibition of
apoptosis has been proposed as a new mechanism for HO-1-med-
iated cytoprotection (Guo et al., 2004). The anti-apoptotic role of
HO-1 in ischemic heart disease (Guo et al., 2004; Togane et al.,
2000), graft rejection (Otterbein et al., 2003), ischemia-reperfusion
injury (Kukoba, Moibenko, & Kotsioruba, 2003), and renovascular
hypertension (Botros et al., 2007) was reported. Increased heme
turnover (Gonzalez-Michaca, Farrugia, Croatt, Alam, & Nath,
2004) and CO production (Reiter & Demple, 2005; Zhang et al.,
2003) was demonstrated to be related with HO-1 mediated anti-
apoptosis. Studies also showed that HO-1 could upregulate the
anti-apoptotic p38 MAPK (Zhang et al., 2003) and Bcl2 expression
(Reiter & Demple, 2005) and inactivate the pro-apoptotic caspase-3
expression (Tang et al., 2004; Zacks et al., 2003). In retina, Ulyano-
va and coworkers reported that HO-1 overexpression could be in-
duced in vitro in Müller cells by conditions of oxidative stress
(Ulyanova et al., 2001). Ocular overexpression of HO-1 was shown
to lower intraocular pressure (Privitera, Potenza, Bucolo, Leggio, &
Drago, 2007), reduce reperfusion-induced injury (Szabo et al.,
2004), and protect RPE cells from oxidative stress-induced death
(Hanneken, Lin, Johnson, & Maher, 2006).
Previously, to investigate the therapeutic function of HO-1, its
accumulation in stressed tissue was achieved by various pharma-
ceutical agents and viral vectors (Abraham, 2003; Abraham et al.,
1995; Melo et al., 2002; Quan et al., 2004). Delivery of HO-1 gene
had been shown to protect the myocardium from ischemia (Melo
et al., 2002), modulate angiotensin II-induced increase in blood
pressure (Yang, Bula, Arroyo, & Chen, 2004), and protect cultured
islets against rTNF-alpha and CHX-mediated cytotoxicity (Li
et al., 2006). Among the various gene delivery vectors, rAAV
vectors are highly efﬁcient at gene transfer in vivo (Pan et al.,
1999, 2000) and can facilitate long-term transduction in animal
models of retinal disease such as laser-induced choroidal neovas-
cularization (Lai et al., 2001), diabetic vascular leakage (Shyong
et al., 2007), and retinal ischemic injury (Wu et al., 2004). In this
study, to induce the retinal overexpression of HO-1 in the rats’
retina, we used rAAV as a vector to deliver HO-1. The effect of
retinal HO-1 overexpression on ONL preservation, photoreceptor
apoptosis, and activated caspase-3 expression was studied.2. Materials and methods
2.1. Generation of rAAV-HO-1
The cDNA coding for mouse HO-1 was ampliﬁed by polymerase
chain reaction (PCR) using a mouse cDNA library as template and
the two oligonucleotides 50-GGATCCACCATGGAGCGTCCACAGCCC
GAC-30/50-GCGGCCGCTTACATGGCATAAATTCCCA-30 as primers. rAAV
encoding HO-1 cDNA or lacZ were constructed by using a three-
plasmid cotransfection system as described previously (Pan et al.,
1999, 2000; Wu et al., 2002). Titers of rAAV-HO-1 and rAAV-lacZ
were determined by dot blot hybridization using HO-1 cDNA and
lacZ as probes (Sun, Li, & Xiao, 2000; Xiao, Li, & Samulski, 1998).
2.2. Animals
Male Sprague–Dawley rats (SD rats) weighing approximately
200 g on arrival, were used in this study. Four groups of age-
matched SD rats were studied: normal control SD rats, SD rats with
experimental RD left untreated, SD rats receiving subretinal rAAV-
HO-1 injection, and SD rats receiving subretinal rAAV-lacZ injec-
tion. There were 45 animals in each group. All the animals were
cared for in accordance with the ARVO Statement for the Use ofAnimals in Ophthalmic and Vision Research. All experimental
procedures used aseptic sterile techniques and were approved by
the Animal Care and Use Committee of the Mackay Memorial
Hospital.
2.3. Subretinal rAAV injection
SD Rats were anesthetized with intramuscular injection of
0.8 mL/kg of an equal-volume mixture of 50 mg/mL ketamine
(Ketalar; Parke-Davis, Morris Plains, NJ) and 2% xylazine (Rompun;
Bayer AG, Leverkusen, Germany). The right eyes were prepared for
subretinal rAAV injection as previously reported (Lai et al., 2001;
Sun et al., 2007; Wu et al., 2002). After pupils were dilated and
the eyeballs were protruded with a rubber sleeve, a sclerotomy
1 mm posterior to temporal limbus was made with the tip of a
30-gauge needle. Retinotomy was then made in the temporal
peripheral retina with the tip of the 30-gauge needle. A Hamilton
syringe equipped with a 33-gauge needle was then introduced
through the sclerotomy and retinotomy into the subretinal space
and 3 lL of viral suspensions (1.1  1010 viral particles) was in-
jected. The needle was left in the subretinal space for 1 min after
injection to reduce the degree of reﬂux. Successful injection was
conﬁrmed by identifying RD in the temporal retina (Lai et al.,
2001; Wu et al., 2002; Zacks et al., 2003).
2.4. Experimental retinal detachment
Three weeks after subretinal rAAV injection, experimental RD
was performed in the right eyes of SD rats by subretinal injection
of sodium hyaluronate (Healon-GV, Pharmacia and Upjohn) (His-
atomi et al., 2002; Wu et al., 2002; Zacks, Zheng, Han, Bakhru, &
Miller, 2004; Zacks et al., 2003). In brief, after anesthetized and
prepared as previously described in subretinal rAAV injection,
the sclera was punctured 1 mm posterior to temporal limbus with
a 30-gauge needle, and then made a retinotomy in the temporal
peripheral retina. A Hamilton syringe equipped with a 33-gauge
needle was slowly advanced into the subretinal space. The sodium
hyaluronate was slowly injected into subretinal space, causing
detachment of the temporal half retina. Eyes with massive subret-
inal hemorrhage, lens trauma or other complication were ex-
cluded. RD was remained essentially stable during the time of
study (28 days) which was conﬁrmed in every animal by surgical
microscope.
2.5. HO-1 activity assay
HO-1 activity assay was performed using a technique (Carraway
et al., 2002; Li & Dai, 2004; Tenhunen, Marver, & Schmid, 1968) in
which bilirubin concentration, the end product of heme degrada-
tion, was determined spectrophotometrically. Brieﬂy, retinas were
homogenized in 0.5 mL phosphate buffer (0.1 mmol/L, pH 7.4) and
incubated on ice with medium consisting of MgCl2 (2 mmol/L,
Invitrogen, CA, USA), Hemin (50 lmol/L, Fluka, Milano, Italy),
NADPH (0.8 mmol/L, Sigma-Aldrich, St. Louis, MO, USA), glucose
6-phosphate (2 mmol/L, Sigma-Aldrich, St. Louis, MO, USA), and
glucose-6-phosphate dehydrogenase (0.0016 U/ll, Sigma-Aldrich,
St. Louis, MO, USA), liver cytosol (5 mg/mL) for 60 min at 37 C(Ab-
del Aziz et al., 2007; Carraway et al., 2002; Li & Dai, 2004). Bilirubin
was then extracted with chloroform and measured on a spectro-
photometer (Spectra MAX190, Molecular Devices, Sunnyvale, CA,
USA) based on optical density (OD) at 464 nm minus 530 nm using
an extinction coefﬁcient of 40 mM1 cm1 (Carraway et al., 2002;
Li & Dai, 2004; Tenhunen et al., 1968). The values are expressed
as nanomoles of bilirubin formed per minute for per milligram pro-
tein. An NADPH-free reaction mixture was provided as blank con-
trol. (Li & Dai, 2004).
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Retinal expression of HO-1 and activated caspase-3 were de-
tected by Western blot analysis. SD rats were sacriﬁced in a CO2
saturated chamber and the eyes were enucleated at 2, 5, 10, and
28 days after creating experimental RD. The retinal tissues were
harvested and prepared for soluble fractions by homogenizing
the retina in Eppendorf tubes containing RIPA lysis buffer
(50 mM Tris, 150 mM NaCl, 10 mM EDTA, 0.1% SDS, 1% NP-40,
0.5% sodium deoxycholate, 1 mM Na3VO4, 1 mM NaF, 1 mM EGTA,
1 mM PMSF, 1 mg/ml leupeptin, and 1 mg/ml pepstatin (Shyong et
al., 2007; Sun et al., 2007; Zacks et al., 2003). Protein (50 lg) from
each animal was extracted for electrophoresis on 10% SDS–poly-
acrylamide gels, and transferred onto a membrane. The membrane
was incubated with antibody speciﬁc to HO-1, HO-2, and activated
caspase-3 (Abcam, Cambridge, USA). The results were then semi-
quantiﬁed by densitometry analysis (Fujiﬁlm LAS3000, Tokyo, Ja-
pan) and normalized using actin levels.
2.7. Immunoﬂuorescence assay
SD rats were sacriﬁced at 2 and 28 days after creating experi-
mental RD, as described previously in Western blot analyses. For
orientation, the temporal sclera was sutured with stitches before
enucleation. The enucleated eyeballs were ﬁxed in 2% paraformal-
dehyde for overnight storage and then embedded in parafﬁn. Ret-
inal tissue sections (5-lm thick) temporal to midline sagittal cut
were collected every 60 lm and transferred to positively charged
slides. They were dewaxed in xylene, progressively hydrated and
then washed three times with phosphate buffer saline and a
1:100 dilution of antibody speciﬁc to HO-1 (Abcam, Cambridge,
USA) (Cukiernik et al, 2004; Shyong et al., 2007; Sun et al., 2007).
A FITC-conjugated anti-mouse IgG was used as the secondary anti-
body. The results were then viewed with a ﬂuorescence micros-
copy (Zeiss Axioplan HBO100, Oberkochen, Germany). The retinas
that were found to have reattached on the day of death were ex-
cluded from further analysis. To quantify the ﬂuorescence inten-
sity, images randomly from six retinal areas (200 lm2) in each
section were photographed with a 20x objective and a similar
exposure time of 2.5 s (Andrieu-Soler et al., 2006; Antonetti et
al., 1998; Shyong et al., 2007). The ﬂuorescence intensity of the
ONL and the inner nuclear layer (INL) was quantiﬁed by using
Adobe Photoshop Histogram algorithm (Adobe Systems, San Jose,
CA, USA) (Andrieu-Soler et al., 2006; Kirkeby & Thomsen, 2005).
Backgrounds were deﬁned as the ﬂuorescence intensity in non-ret-
inal ﬁelds and then subtracted from the values obtained for ONL
(Andrieu-Soler et al., 2006;Kinney et al., 2006; Kirkeby & Thomsen,
2005). Values for ﬂuorescence intensity were then calculated and
expressed as means ± SD.
2.8. Morphology studies
The SD rats were sacriﬁced and enucleated for morphology
study at 28 days of RD. The temporal sclera was sutured with
stitches for orientation. After enucleation, the cornea and lens were
removed. The remaining eyecups were placed in ﬁxative contain-
ing 1.5% glutaraldehyde and 2% paraformaldehyde at 4 C for over-
night storage (Zacks et al., 2003) and then embedded in parafﬁn.
Vertical sections (5-lm thick) temporal to midline were cut
through the optic nerve head and collected every 60 lm. These
sections were dewaxed in xylene, progressively hydrated and
stained with haematoxylin–eosin for histological evaluation (Wu
et al., 2002; Zacks et al., 2003). The retinas that were found to have
reattached on the day of death were excluded from further analy-
sis. Measurements of ONL thickness and haematoxylin–eosinpositive photoreceptor nuclei of detached retina were taken every
60 lm in each section and combined to obtain an average.
2.9. In situ TUNEL labeling
Experimental eyes were obtained 2, 5, 10 days after initiating
RD and processed for TUNEL assay. The TUNEL assay was per-
formed with a DNA fragmentation detection kit (Calbiochem,
Darmstadt, Germany) on 5-lm thick parafﬁn-embedded eye sec-
tions, as described previously in immunoﬂuorescence assay (Wu
et al., 2002). The TUNEL assay ﬂuorescence signals were viewed
with a Zeiss Axioplan HBO 100 ﬂuorescence microscope. The total
numbers of TUNEL-positive nuclei every 450 lm of detached retina
in each section were counted and combined to obtain an average
(Hisatomi et al., 2002; Wu et al., 2002; Zacks et al., 2003).
2.10. Statistical analyses
The results were expressed as means ± SD. We used the Krus-
kal–Wallis test to compare the differences in ONL thickness, photo-
receptor nuclei count, ONL ﬂuorescence intensities, retinal
expression of activated caspase-3, and the total numbers of TUN-
EL-positive nuclei between eyes receiving rAAV-HO-1 and rAAV-
lacZ injection and eyes with RD left untreated. All P values are
2-tailed and differences are considered to be statistically
signiﬁcant for p < 0.05.
3. Results
3.1. Overexpression of HO-1 in the retina after subretinal injection of
rAAV-HO-1
Fig. 1A shows the retinal overexpression of HO-1 induced by
rAAV-HO-1 injection. There was no retinal HO-1 was noted in nor-
mal control eye. Minimal HO-1 expression was detected in eyes
with RD left untreated and eyes with RD receiving rAAV-lacZ injec-
tion at 2 and 5 days of RD. After densitometric quantiﬁcation, HO-1
expression was signiﬁcantly increased in rAAV-HO-1 treated eyes
at 2 (RD left untreated: 4.12 ± 0.23 pixels, rAAV-HO-1:
17.2 ± 2.25 pixels, rAAV-lacZ: 3.98 ± 0.3 pixels, Kruskal–Wallis test,
n = 3 from three animals in each group, p = 0.018), 5 (RD left
untreated: 2.90 ± 0.26 pixels, rAAV-HO-1: 16.1 ± 3.34 pixels,
rAAV-lacZ: 3.55 ± 0.79 pixels Kruskal–Wallis test, n = 3 from three
animals in each group, p = 0.018), 10 (RD left untreated: 2.92 ± 0.
55 pixels, rAAV-HO-1: 15.5 ± 2.0 pixels, rAAV-lacZ: 2.71 ± 0.35 pix-
els Kruskal–Wallis test, n = 3 from three animals in each group,
p = 0.018), and 28 (RD left untreated: 2.67 ± 0.34 pixels, rAAV-
HO-1: 14.2 ± 1.98 pixels, rAAV-lacZ: 2.56 ± 0.23 pixels Kruskal–
Wallis test, n = 3 from three animals in each group, p = 0.018) days
of RD (Fig. 1B). Retinal expression of HO-2 in normal control eye,
eyes with RD left untreated, and eyes with RD receiving rAAV
injection was not signiﬁcantly changed (Fig. 1A).
The HO-1 activity was measured by the formation of bilirubin in
retina (Carraway et al., 2002; Li & Dai, 2004; Tenhunen et al., 1968,
Fig. 1C). It was 1.8 ± 0.21 nmol bilirubin/mg/min in normal control
eye. The HO-1 activity was signiﬁcantly increased in rAAV-HO-1
injected eyes at 2 (RD left untreated: 1.77 ± 0.23 nmol bilirubin/
mg/min, rAAV-HO-1: 16.2 ± 1.01 nmol bilirubin/mg/min, rAAV-
lacZ: 2.01 ± 0.3 nmol bilirubin/mg/min Kruskal–Wallis test, n = 3
from three animals in each group, p = 0.011), 5 (RD left untreated:
2.12 ± 0.09 nmol bilirubin/mg/min, rAAV-HO-1: 14.0 ± 0.99 nmol
bilirubin/mg/min, rAAV-lacZ: 1.98 ± 0.23 nmol bilirubin/mg/min
Kruskal–Wallis test, n = 3 from three animals in each group,
p = 0.011), 10 (RD left untreated: 2.13 ± 0.11 nmol bilirubin/mg/
min, rAAV-HO-1: 15.5 ± 1.79 nmol bilirubin/mg/min, rAAV-lacZ:
Fig. 1. Retinal HO-1 overexpression induced by rAAV-HO-1. (A) SD rats were enucleated and the retinal tissues were harvested for Western blot analysis at 2, 5, 10, and 28
days of RD. Each blot is a representative of the results from three rats. (B) Densitometry of values of HO-1 disclosed that HO-1 was signiﬁcantly increased: in eyes treated with
rAAV-HO-1 than in eyes treated with rAAV-lacZ and eyes with RD left untreated at 2, 5, 10, and 28 days of RD. (: Kruskal–Wallis test, n = 3 in each group, p < Q.05J. (C) HO-1
activity was measured and expressed as nanomoles of bilirubin per milligram of protein per minute (: Kruskal–Wallis test, n = 3 in each group, p < 0.05) C; control. UT: eyes
with RD left untreated.
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three animals in each group, p = 0.011) and 28 (RD left untreated:
1.77 ± 0.25 nmol bilirubin/mg/min, rAAV-HO-1: 13.5 ± 1.22 nmol
bilirubin/mg/min, rAAV-lacZ: 1.98 ± 0.23 nmol bilirubin/mg/min
Kruskal–Wallis test, n = 3 from three animals in each group,
p = 0.011) days of RD (Fig. 1C).
To further conﬁrm the induction of HO-1 in the retina after gene
transfer, an immunoﬂuorescence assay was performed with an
anti-HO-1 antibody. HO-1 immunoﬂuorescence was demonstrated
in the retinal ONL of rAAV-HO-1 treated eyes (Fig. 2C) at 2 days of
RD. No HO-1 immunoﬂuorescence was observed in normal control
eyes (Fig. 2A), eyes with RD left untreated (Fig. 2B and E), and
rAAV-lacZ treated eyes (Fig. 2D and G). HO-1 immunoﬂuorescence
was still present in the ONL of rAAV-HO-1 treated eyes at 28 days
of RD (Fig. 2F). These results conﬁrmed the induction of HO-1
expression in rAAV-HO-1 treated retina.
Quantitative analyses of the relative HO-1 ﬂuorescence values
in the ONL were 29.61 ± 1.72 for normal control eyes,
31.25 ± 2.56 for eyes with RD left untreated, 85.04 ± 3.12 for
rAAV-HO-1 treated eyes, and 29.90 ± 1.00 for rAAV-lacZ-injected
eyes at 2 days of RD (Fig. 3). There was a signiﬁcant increase in
HO-1 ﬂuorescence in rAAV-HO-1 treated eyes compared with
rAAV-lacZ treated and eyes with RD left untreated (Kruskal–Wallis
test, n = 5 from 5 animals in each group, p = 0.003). At 28 days of
RD, relative HO-1 ﬂuorescence values in the ONL were
29.89 ± 1.66 for normal control eyes, 29.9 ± 1.0 for eyes with RDleft untreated, 78.06 ± 3.34 for rAAV-HO-1 treated eyes, and
32.86 ± 2.9 for rAAV-lacZ treated eyes (Fig. 3). As shown previ-
ously, HO-1 ﬂuorescence in the ONL was higher in rAAV-HO-1-
treated eyes than in rAAV-lacZ-injected eyes or eyes with RD left
untreated (Kruskal–Wallis test, n = 5 from ﬁve animals in each
group, p = 0.007).
3.2. Morphology and quantitative analysis of the ONL
Twenty-eight days after creating RD, the SD rats were sacriﬁced
and enucleated for morphology study. Representative images were
shown in Fig. 4A. Degeneration of the retinal photoreceptor outer
segment (OS) and inner segment (IS) was noted in eyes treated
with rAAV-lacZ or eyes with RD left untreated compared with
normal control eyes. The ONL was signiﬁcantly shortened in eyes
treated with rAAV-lacZ, or eyes with RD left untreated than in
rAAV-HO-1 treated eyes and normal control eyes. The quantitative
analysis of ONL thickness in the eyes receiving different treatments
at 28 days of RD was shown in Fig. 4B. The mean ONL thickness
was 42.15 ± 3.18 lm in normal control eyes and 33.11 ± 3.76 lm
in rAAV-HO-1 treated eyes. The mean ONL thickness was
26.14 ± 1.86 lm in rAAV-lacZ treated eyes, and 25.56 ± 2.20 lm
in eyes with RD left untreated. The ONL thickness (Kruskal–Wallis
test, n = 6 from 6 animals in each group, p = 0.018) was signiﬁ-
cantly preserved in rAAV-HO-1 treated eyes compared with
rAAV-lacZ treated eyes at 28 days of RD. The mean photoreceptor
Fig. 2. Representative retinal sections following immunostaining for HO-1. SD rats were infected with rAAV-HO-1 (C and F) or rAAV-lacZ (D and G) or left untreated (B and E),
At 2 days (B–D) and 28 days (E–G) of RD, SD rats were enucleated and subjected to immunostaining analysts with HO-1 speciﬁc antibodies, INL ; inner nuclear layer. ONL:
outer nuclear layer Original magniﬁcation: 200. UT: eyes with RD left untreated. Scale bar: 20 lm.
Fig. 3. Quantitative analysis of the anti-HO-1 ﬂuorescence intensity in retina.
Relative ﬂuorescence intensities in outer nuclear layer (GNU) were represented by
histograms. Relative ﬂuorescence in the ONL shows a signiﬁcant increase of
intensities in eyes injected with rAAV-HO-1 than in eyes receiving rAAV-lacZ and
eyes without treatment at 2 and 28 days of RD. (: Kruskal–Wallis test, n = 5 from
ﬁve animals in each group, p < 0.05). UT: eyes with RD left untreated.
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8.92 ± 0.77 rows in rAAV-HO-1 treated eyes at 28 days of RD. It
was 5.90 ± 0.46 rows in rAAV-lacZ treated eyes, and 6.01 ± 0.41
rows in eyes with RD left untreated (Fig. 4C). The mean photore-
ceptor nuclei count was signiﬁcantly higher in rAAV-HO-1 treated
eyes compared with rAAV-lacZ treated eyes and eyes with RD left
untreated at 28 days of RD (Kruskal–Wallis test, n = 6 from 6
animals in each group, p = 0.009).
3.3. Effects of HO-1 overexpression on photoreceptor apoptosis
The eyes were enucleated for TUNEL assay at 2, 5, and 10 days
after creation of RD. Representative images of eyes receiving differ-
ent treatments are shown in Fig. 5A. No TUNEL-positive nuclei
were observed in normal control eyes. Representative images at
2 days of RD disclosed that there were fewer TUNEL-positive nuclei
in the ONL of detached retina in rAAV-HO-1 treated eyes comparedwith eyes treated with rAAV-lacZ and eyes with RD left untreated.
After counting TUNEL-positive nuclei in the retina, the mean apop-
totic cells per 450 lm of retina was 3.38 ± 0.59 in rAAV-HO-1 trea-
ted eyes, 10.90 ± 1.99 in rAAV-lacZ treated eyes, and 11.12 ± 1.23
in eyes with RD left untreated at 2 days of RD. The apoptotic cells
diminished gradually at 5 and 10 days of RD. The mean apoptotic
cells per 450 lm of retina at 5 days of RD was 4.02 ± 0.45 in
rAAV-HO-1 treated eyes, 8.11 ± 1.13 in rAAV-lacZ treated eyes,
and 7.55 ± 0.99 in eyes with RD left untreated. At 10 days of RD,
the mean apoptotic cells per 450 lm of retina was 3.01 ± 0.58 in
rAAV-HO-1 treated eyes, 3.79 ± 0.4 in rAAV-lacZ treated eyes, and
4.06 ± 0.62 in eyes with RD left untreated. Quantitative analysis
showed that there was signiﬁcantly fewer TUNEL-positive nuclei
in rAAV-HO-1 treated eyes than in rAAV-lacZ treated eyes and eyes
with RD left untreated at 2 (Kruskal–Wallis test, n = 5 from ﬁve
animals in each group, p = 0.008) and 5 days (Kruskal–Wallis test,
n = 5 from ﬁve animals in each group, p = 0.018)of RD (Fig. 5B).
There was no statistical difference at 10 days of RD between eyes
treated with either rAAV-HO-1, rAAV-lacZ or eyes with RD left un-
treated (Kruskal–Wallis test, n = 5 from ﬁve animals in each group,
p = 0.45).
3.4. Effects of HO-1 overexpression on activated caspase-3 expression
Eyes receiving different treatments were enucleated at 2, 5, and
10 days of RD for Western blot analysis using antibodies speciﬁc
for activated caspase-3. The retinal expression of activated cas-
pase-3 was higher in eyes treated with rAAV-lacZ and eyes with
RD left untreated compared with normal control eyes and rAAV-
HO-1 treated eyes at 2 days of RD (Fig. 6A). After that, it gradually
diminished. Quantiﬁed activated retinal capase-3 was 4.00 ± 0.55
pixels in normal control eye, At 2 days of RD, it was 7.75 ± 0.89 pix-
els in rAAV-HO-1 treated eyes, 14.29 ± 1.15 pixels in rAAV-lacZ
treated eyes, and 15.35 ± 1.21 pixels in eyes with RD left untreated
(Fig. 6B). The activated caspase-3 at 5 days of RD was 4.92 ± 1.12
pixels in rAAV-HO-1 treated eyes, 6.34 ± 0.99 in rAAV-lacZ treated
eyes, and 5.12 ± 0.78 pixels in eyes with RD left untreated. At 10
days of RD, the retinal activated caspasse-3 was 4.76 ± 0.46 pixels
Fig. 4. The effect of HO-1 on detached retina. (A) Representative images showing
the differences of retinal thickness between eyes receiving different treatments at
28 days of RD. (B) Quantitative analysis of ONL thickness and (C) photoreceptor
nuclei count at 28 days of RD, The mean ONL thickness f: Kruskal–Wallis test, n = 6
from 6 animals in each group. p = 0.0i8), and photorecepicr nuclei count {:
Kruskal–Wallis test, n = 6b p = G.QQ9) were signiﬁcantly preserved in eyes I rested
with rAAV-HQ-1 Ihan in eyes Irealad with rAAV-lacZ, and eyes without ireaiment at
26 days of RD, 1NL; inner nuclear layer, ONL: outer nuclear layer. UT: eyes with RD
left untreated. Haematoxylin and eosin staining. Original magniﬁcation; 200 scale
bar 20 lm.
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eyes, and 5.33 ± 1.09 pixels in eyes with RD left untreated. Quanti-
tative analysis showed that the activated caspase-3 induced by
experimental RD was signiﬁcantly reduced in rAAV-HO-1 treated
eyes compared with rAAV-lacZ treated eyes (Kruskal–Wallis test,
n = 5 from ﬁve animals in each group, p = 0.008) at 2 days of RD.
There was no statistical difference at 5 (Kruskal–Wallis test, n = 5
from ﬁve animals in each group, p = 0.23) and 10 (Kruskal–Wallis
test, n = 5 from ﬁve animals in each group, p = 0.45) days of RD be-
tween eyes treated with either rAAV-HO-1, rAAV-lacZ or eyes with
RD left untreated.
4. Discussion
RD is a common cause of visual impairment in humans (Lewis
et al., 2002). Unfortunately, RD patients may suffer from visual
impairment even after successful reattachment surgery (Braziti-
kos, 2000; Hisatomi et al., 2002). Photoreceptor apoptosis has been
implicated in poor visual prognosis after RD (Erickson et al., 1983;
Fisher & Anderson, 2001). This study was designed to evaluate the
protective efﬁcacy of retinal HO-1 overexpression in attenuating
the photoreceptor apoptosis caused by experimental RD. To induce
HO-1 overexpression, subretinal HO-1 gene delivery via a rAAVvector was used. Our results showed that there were fewer apop-
totic photoreceptors (Figs. 5 and 6) in rAAV-HO-1 treated eyes
compared with rAAV-lacZ-treated eyes and RD left untreated eyes.
At 28 days of RD, the ONL was much more preserved in eyes trea-
ted with rAAV-HO-1 than in eyes treated with rAAV-lacZ and RD
left untreated eyes (Fig. 4). These results suggest that rAAV-medi-
ated HO-1 gene delivery in the retina may attenuate the photore-
ceptor death induced by experimental RD.
HO-1 is an enzyme that can catalyze the oxidative degradation of
heme to biliverdin, CO, and iron (Otterbein et al., 2000b; Guo et al.,
2004; Morita et al., 1995; Stocker et al., 1987; Togane et al., 2000).
The anti-apoptotic effect of HO-1 overexpression was disclosed in
ischemic heart disease (Guo et al., 2004; Togane et al., 2000), graft
rejection (Otterbein et al., 2003), and renovascular hypertension
(Botros et al., 2007). In retina, it was reported that HO-1 could be in-
duced after hypoxia (Ulyanova et al., 2001), ischemia-reperfusion
injury (Szabo et al., 2004), and intense light exposure (Sun et al.,
2007). Evidences showed that over-expressed HO-1 could increase
heme turnover (Gonzalez-Michaca et al., 2004), increase COproduc-
tion (Reiter & Demple, 2005; Zhang et al., 2003), and inactivate the
pro-apoptotic caspase-3 expression (Guo et al., 2004; Tang et al.,
2004; Togane et al., 2000; Zacks et al., 2003). Recently, there were
growing evidences disclosed that CO could also upregulate anti-
apoptotic p38MAPK (Zhang et al., 2003) and Bcl2 expression (Reiter
& Demple, 2005). CO releasing molecules have also been developed
to facilitate CO delivery and lacked the ability to induce HO-1 (Mot-
terlini et al., 2002). More experiments are necessary to evaluate if
CO could have a similar effect as rAAV-HO-1 in attenuating RD in-
duced photoreceptor apoptosis.
The photoreceptor apoptosis induced by experimental RD was
reported to be activated by the FAS/FAS ligand system (Zacks
et al., 2003; Zacks et al., 2004) or through an intrinsic pathway
modiﬁed by intracellular proteins (Hisatomi et al., 2002). TUNEL-
positive apoptotic photoreceptors appeared to reach a maximum
on day 3 of RD and gradually diminished (Hisatomi et al., 2002).
Time dependent caspase-3 activation played an important role in
the transduction pathway of the apoptotic cascade (Cook et al.,
1995; Zacks et al., 2003). Modulation of the apoptotic cascade
has been shown to alter the rate and amount of photoreceptor
apoptosis in animal models of RD (Yang et al., 2004; Zacks et al.,
2003; Zacks et al., 2004). In the present study, we showed that less
activated caspase-3 expression at 2 days of RD (Fig. 6) accompa-
nied with fewer TUNEL-positive nuclei in ONL at 2 and 5 days of
RD (Fig. 5) was noted in rAAV-HO-1 treated eyes compared with
rAAV-lacZ treated eyes or RD left untreated eyes. Combined these
ﬁndings, it supported an important role of HO-1 in attenuating
photoreceptor apoptosis induced by experimental RD through
modulation of caspase-3 activation. This effect might contribute
to better preservation of visual function in RD patients.
By use of a viral vector delivering HO-1 gene, overexpression of
HO-1 was shown to protect the myocardium from ischemia (Melo
et al., 2002), modulate angiotensin II-induced increase in oxidative
injury (Quan et al., 2004), and protect cultured islets against rTNF-
alpha and CHX-mediated cytotoxicity (Li et al., 2006). The rAAV
vectors were demonstrated to be capable of mediating efﬁcient
and prolonged transgene expression (Bainbridge, Tan, & Ali,
2006; Rolling, 2004). Our previous works demonstrated that rAAV
vectors were highly efﬁcient gene-delivery systems which could
facilitate long-term transduction in animal models of retinal dis-
eases (Lai et al., 2001; Shyong et al., 2007; Wu et al., 2002,
2004). In this study, we reported that subretinal delivery of HO-1
gene via a rAAV vector induced HO-1 overexpression in the retinal
ONL (Fig. 2). However, increased HO-1 expression is not an indica-
tion of increased HO-1 activity (Sardana & Kappas, 1987). We mea-
sured HO-1 activity by the formation of bilirubin in retina
(Carraway et al., 2002; Li & Dai, 2004; Tenhunen et al., 1968) and
Fig. 5. The effect of HO-1 on reducing photoreceptor apoptosis (A) Eyes from rats receiving different treatments were enucleated for TUNEL assay. Representative images
showed TUNEL-positive photoreceptor nuclei at 2 days of RD. Original magniﬁcation: 200. (B) Quantitative analysis of TUNEL assay TUNEL-positive photoreceptor nuclei
were signiﬁcantly reduced in rAAVHO-1 treated eyes compared with eyes injected with rAAV-lacZ and eyes without treatment at 2 and 5 days of RD. (: Kruskal–Waltis test,
n = 5 from ﬁve animals in each group, p < 0,05). ENL: inner nuclear layer. ONL: outer nuclear layer. UT: eyes with RD left untreated. Scale bar: 20 lm.
Fig. 6. The effect of HO-1 on retinal activated caspase-3 expression. (A) Eyes of SD rats previously treated wilh rAAV-HO-1, rAAV-lacZ, normal control eyes, and eyes with RD
left untreated were prepared and subjected to Western blot analysis of activated caspssc-3. Each blot is a representative of the results from ﬁve rats. (B) After densitometric
scans, values of activated caspase-3 were normalized to act in. The activated capase-3 was signiﬁcantly reduced in eyes Irealed with rAAV-HCM than in eyes treated with
rAAV-lacZ and eyes without treatment at 2 days of RD (: Kruskal–Wallis test. n = 5 in each group, p = 0.008). UT: eyes with RD left untreated.
2400 M.-P. Shyong et al. / Vision Research 48 (2008) 2394–2402disclosed increased HO-1 expression by rAAV-HO-1 was accompa-
nied with increased HO-1 activity (Fig. 1C). This transgenic rAAV-
HO-1 expression led to attenuate RD induced photoreceptor
apoptosis associated with better ONL preservation without
repeated subretinal injection.
Evidences disclosed that HO-1 was induced mainly in Müller
cells, but not photoreceptors, after exposure to stressful stimuli
(Szabo et al., 2004; Ulyanova et al., 2001) and intense light (Sun
et al., 2007). Due to its anti-apoptotic ability, overexpression of
HO-1 in photoreceptor might protect them from RD-induced apop-
tosis. In the retina, following subretinal delivery, rAAV vectorscould transduce RPE and photoreceptor (Ali et al.,1996; Ali et al.,
1998; Bennett et al., 1999). In present study, we demonstrated that
localized high HO-1 gene expression was noted in the ONL after
subretinal injection of rAAV-HO-1 (Fig. 4). Thus, it seems that spe-
ciﬁc and high expression of HO-1 in the ONL after subretinal injec-
tion is essential to attenuate photoreceptor apoptosis induced by
RD (Kinney et al., 2006).
This report demonstrates that overexpression of HO-1 can re-
duce the photoreceptor apoptosis induced by experimental RD.
Our results showed that subretinal rAAV-HO-1 injection could lead
retinal HO-1 overexpression localized in ONL. Transduction of
M.-P. Shyong et al. / Vision Research 48 (2008) 2394–2402 2401HO-1 gene by rAAV in the retina provided a better protection from
RD-induced apoptosis. This novel strategy could offer the beneﬁt of
a long-lasting protective effect without the need for repeated injec-
tion. These advantages could serve as the basis for an adjunctive
treatment for patients suffering from RD to reduce the risk of per-
manent visual loss even after successful reattachment surgery.Acknowledgments
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